Cybrexa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of CBX-12 (alphalex™-exatecan) in Advanced or Metastatic Refractory Solid Tumors

NEXT STORY
Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting
PREV STORY
G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation

Once granted, the new formulation patent is expected to be valid until at least ...

author_avatar
NASDAQ Market News

invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline

author_avatar
NASDAQ Market News

Teladoc Health Reports Fourth-Quarter and Full-Year 2018 Results

author_avatar
NASDAQ Market News